We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Flex Pharma adjourned the special meeting until July 12, 2019 in order to provide shareholders with more time to complete proxies and vote their shares.
Christoph Westphal is at it again. Not quite a year after stepping down from his CEO role at Flex Pharma, the serial biotech entrepreneur launched another Boston area-based company: T-Scan Therapeutics.